NO20070061L - 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav - Google Patents

3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav

Info

Publication number
NO20070061L
NO20070061L NO20070061A NO20070061A NO20070061L NO 20070061 L NO20070061 L NO 20070061L NO 20070061 A NO20070061 A NO 20070061A NO 20070061 A NO20070061 A NO 20070061A NO 20070061 L NO20070061 L NO 20070061L
Authority
NO
Norway
Prior art keywords
ribofuranosylthiazolo
beta
compounds
nucleosides
pyridimine
Prior art date
Application number
NO20070061A
Other languages
English (en)
Inventor
David Louis Clark
Stephen E Webber
Devron R Averett
Erik J Rueden
Joseph R Lennox
Alan X Xiang
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34959084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070061(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of NO20070061L publication Critical patent/NO20070061L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

3-p-D-ribofuranosyltiazolo[4,5-d]pyrimidinnukleosider og anvendelser derav. Oppfinnelsen er rettet mot 3-P-D-ribomranosyltiazolo[4,5Ki]pyridiminnukleosider og farmasøytiske sammensetninger som inneholder slike forbindelser som har immuno-modulatorisk aktivitet. Oppfinnelsen er også rettet mot den terapeutiske eller profylaktisk bruk av slike forbindelser og sammensetninger og til metoder for å behandle sykdommer og forstyrrelser beskrevet her, ved å administrere effektive mengder av slike forbindelser.
NO20070061A 2004-06-07 2007-01-04 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav NO20070061L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/018011 WO2005121162A1 (en) 2004-06-07 2004-06-07 3-β-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF

Publications (1)

Publication Number Publication Date
NO20070061L true NO20070061L (no) 2007-03-05

Family

ID=34959084

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070061A NO20070061L (no) 2004-06-07 2007-01-04 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav

Country Status (21)

Country Link
US (1) US20080070852A1 (no)
EP (1) EP1758916B1 (no)
JP (1) JP4856638B2 (no)
CN (1) CN1964985A (no)
AR (1) AR049203A1 (no)
AU (1) AU2004320625B2 (no)
BR (1) BRPI0418887A (no)
CA (1) CA2566541C (no)
ES (1) ES2399891T3 (no)
IL (1) IL179529A0 (no)
IS (1) IS8575A (no)
MX (1) MXPA06014182A (no)
NO (1) NO20070061L (no)
PA (1) PA8635901A1 (no)
PE (1) PE20060455A1 (no)
RU (1) RU2006146204A (no)
SV (1) SV2006002135A (no)
TN (1) TNSN06403A1 (no)
TW (1) TW200612969A (no)
UY (1) UY28943A1 (no)
WO (1) WO2005121162A1 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009486D0 (en) 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
ES2525567T3 (es) * 2004-12-17 2014-12-26 Anadys Pharmaceuticals, Inc. Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y profármacos de los mismos
UA100666C2 (uk) 2006-04-11 2013-01-25 Новартіс Аг Інгібітори нсv/віл та їх застосування
GB0609178D0 (en) * 2006-05-09 2006-06-21 Univ Cardiff Novel compounds
CL2007001427A1 (es) * 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
BRPI0717741A2 (pt) * 2006-10-17 2014-04-08 Anadys Pharmaceuticals Inc Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença
ES2530763T3 (es) * 2007-06-25 2015-03-05 Anadys Pharmaceuticals Inc Procedimiento continuo de hidrólisis enzimática
EP2019113A1 (en) * 2007-07-26 2009-01-28 Anadys Pharmaceuticals, Inc. New Crystalline Salts of 5-Amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
JP5767643B2 (ja) * 2009-09-21 2015-08-19 ギリード・サイエンシズ・インコーポレーテッド １’−置換カルバヌクレオシド類似体の調製のためのプロセスおよび中間体
WO2012048235A1 (en) 2010-10-08 2012-04-12 Novartis Ag Vitamin e formulations of sulfamide ns3 inhibitors
CN102153548B (zh) * 2011-02-24 2012-11-28 河北大学 一种含有噻唑（嗪）烷酮环的类核苷衍生物及其制备方法和其在药物制剂中的应用
TW202345800A (zh) * 2022-04-06 2023-12-01 美商維納拓爾斯製藥公司 口服生物可利用的核苷類似物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880784A (en) * 1987-12-21 1989-11-14 Brigham Young University Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives
US5041426A (en) * 1987-12-21 1991-08-20 Brigham Young University Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides
EA008380B1 (ru) 2001-11-27 2007-04-27 Анадис Фармасьютикалз, Инк. 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ

Also Published As

Publication number Publication date
CA2566541C (en) 2012-10-09
RU2006146204A (ru) 2008-07-20
ES2399891T3 (es) 2013-04-04
PA8635901A1 (es) 2006-07-03
JP4856638B2 (ja) 2012-01-18
US20080070852A1 (en) 2008-03-20
AU2004320625B2 (en) 2009-08-27
CA2566541A1 (en) 2005-12-22
AU2004320625A1 (en) 2005-12-22
PE20060455A1 (es) 2006-06-19
BRPI0418887A (pt) 2007-10-30
TW200612969A (en) 2006-05-01
EP1758916A1 (en) 2007-03-07
IS8575A (is) 2006-12-05
EP1758916B1 (en) 2012-11-21
JP2008501792A (ja) 2008-01-24
CN1964985A (zh) 2007-05-16
AR049203A1 (es) 2006-07-05
SV2006002135A (es) 2006-05-08
MXPA06014182A (es) 2007-06-25
WO2005121162A1 (en) 2005-12-22
UY28943A1 (es) 2006-01-31
IL179529A0 (en) 2007-05-15
TNSN06403A1 (en) 2008-02-22

Similar Documents

Publication Publication Date Title
NO20070061L (no) 3-beta-D-ribofuranosyltiazolo[4,5-d]pyridiminnukleosider og anvendelser derav
TNSN07208A1 (en) 3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
YU45204A (sh) 3-BETA-D-RIBOFURANOZILTIAZOLO/4,5-d/ PIRIMIDINSKI NUKLEOZIDII NJIHOVA UPOTREBA
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
WO2006004741A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
WO2006004684A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
TW200611695A (en) Pyrrolopyridine derivatives
NO20053792L (no) Heterocykly-3-sulfonylindazoler som 5-hydroksytryptamin-6 ligander
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
WO2005115392A3 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
NO20064974L (no) terapeutiske midler
WO2002079169A8 (en) Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
WO2002079149A3 (en) Novel cyano-substituted dihydropyrimidine compounds and their use to treat diseases
AU2003260436A1 (en) Pyrimidine compounds
ATE451350T1 (de) Arylalkylsulfonamide als therapeutische mittel zur behandlung von knochenleiden
UA83142C2 (en) 3-aminocyclopentane carboxyamidine as modulators of chemokine receptors
UA91697C2 (en) 3, 5-DISUBSTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d]PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
DOP2005000261A (es) Compuestos de 3h-oxazolo y 3h-tiazolo [4,5-d] pirrimidin-2-ona 3,5-disustituida y 3,5,7-trisustituida y profarmacos de los mismo
IL160604A0 (en) C2-disubstituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application